$10.15 +0.37 (%) Biocryst Pharmaceuticals Inc - NASDAQ

Oct. 1, 2014 | 04:00 PM

Partner Headlines

  1. Ebola-Related Pharma Stocks Soar On First U.S. Case

    IBD | Oct. 1, 2014 | 14:20PM EST
  2. Morning Market Movers

    Benzinga | Oct. 1, 2014 | 09:39AM EST
  3. Making Money With Charles Payne: 09/30/14

    FoxBusiness | Oct. 1, 2014 | 06:18AM EST
  4. Dow Jumps 170 Points; Bed Bath & Beyond Shares Rise On Upbeat Results

    Benzinga | Sep. 24, 2014 | 15:54PM EST
  5. U.S. Stocks Rise; Accenture Shares Decline On Weak Forecast

    Benzinga | Sep. 24, 2014 | 13:17PM EST
  6. BioCryst Receives Additional NIAID Funding For Manufacture and Development Of BCX4430, $19.9M Has Been Awarded To Date Under The Contract

    Benzinga | Sep. 18, 2014 | 12:08PM EST
  7. Momentum Stocks Showing Weakness

    Benzinga | Sep. 15, 2014 | 17:33PM EST
  8. BioCryst Announces RAPIVAB Trial Results For The Treatment Of Influenza At The ICAAC 2014 Meeting

    Benzinga | Sep. 6, 2014 | 11:23AM EST
  9. BioCryst Pharmaceuticals, Inc. Sinks; WHO Notes Ebola Safety Data Unavailable

    Benzinga | Sep. 5, 2014 | 13:18PM EST
  10. BioCryst To Present Peramivir Trial Results For The Treatment Of Influenza At The ICAAC 2014 Meeting

    Benzinga | Sep. 2, 2014 | 06:53AM EST
  11. US Stock Futures Gain Ahead Of Consumer Data

    Benzinga | Aug. 29, 2014 | 07:32AM EST
  12. Biotechs That Might Benefit From Ebola

    Benzinga | Aug. 11, 2014 | 15:29PM EST
  13. Benzinga's Top #PreMarket Gainers

    Benzinga | Aug. 11, 2014 | 08:05AM EST
  14. Stocks Hitting 52-Week Highs

    Benzinga | Aug. 8, 2014 | 10:21AM EST
  15. Benzinga's Top Initiations

    Benzinga | Aug. 8, 2014 | 09:15AM EST
  16. JP Morgan Initiates BioCryst Pharmaceuticals At Overweight

    Benzinga | Aug. 8, 2014 | 08:38AM EST
  17. MLV & Co Sees Positive Momentum Going Into 2H14 For BioCryst Pharmaceuticals

    Benzinga | Aug. 7, 2014 | 09:36AM EST
  18. Ebola Stocks Continue Higher

    Benzinga | Aug. 4, 2014 | 14:14PM EST
  19. UPDATE: Wells Fargo Upgrades BioCryst

    Benzinga | Jun. 23, 2014 | 13:34PM EST
  20. UPDATE: H.C. Wainwright & Co. Initiates Coverage on BioCryst Pharmaceuticals on Positive Expectations for Oral HAE Drug

    Benzinga | Mar. 10, 2014 | 09:11AM EST
  21. Benzinga's Top Initiations

    Benzinga | Mar. 10, 2014 | 08:41AM EST
  22. Morning Movers for Feb. 25, 2014: IMUC, MSO, ZU, CARA, VSI, TSLA, XOMA, BCRX Moving Higher, RP, ODP, VVUS, AINV, MGIC, ALSN Lower

    Benzinga | Feb. 25, 2014 | 09:41AM EST
  23. Benzinga's Top #PreMarket Gainers

    Benzinga | Feb. 25, 2014 | 08:08AM EST
  24. Benzinga's Top Downgrades

    Benzinga | Jan. 27, 2014 | 08:03AM EST
  25. Benzinga's Top Initiations

    Benzinga | Jan. 21, 2014 | 09:53AM EST
  26. UPDATE: JMP Securities Places BioCryst Pharmaceuticals PT Under Review, Awaiting Details

    Benzinga | Jan. 13, 2014 | 10:32AM EST
  27. US Stock Futures Gain Ahead Of GDP Data

    Benzinga | Dec. 20, 2013 | 07:11AM EST
  28. BioCryst Files Peramivir NDA for Influenza

    Benzinga | Dec. 20, 2013 | 06:31AM EST
  29. Benzinga's Top #PreMarket Gainers

    Benzinga | Dec. 18, 2013 | 08:36AM EST
  30. BioCryst Selects Two Plasma Kallikrein Inhibitors for Hereditary Angioedema into Preclinical Development

    Benzinga | Dec. 18, 2013 | 07:09AM EST
  31. BioCryst Initiates Phase 2a Clinical Trial of BCX4161 in Patients with Hereditary Angioedema

    Benzinga | Nov. 7, 2013 | 11:53AM EST
  32. Benzinga's Top Pre-Market Gainers

    Benzinga | Sep. 17, 2013 | 08:11AM EST
  33. BioCryst Awarded Up to $22M Contract by the NIAID to Develop BCX4430 for the Treatment of Marburg Virus Disease

    Benzinga | Sep. 17, 2013 | 07:06AM EST
  34. JMP Calls BioCryst's Oral Kallikrein 'Potential Game Changer,' Believes ViroPharma, Shire Could Be Interested

    Benzinga | Aug. 28, 2013 | 14:43PM EST
  35. UPDATE: JMP Securities Raises PT on BioCryst Pharmaceuticals on Potential Game Changer

    Benzinga | Aug. 28, 2013 | 11:20AM EST
  36. Benzinga's Top Pre-Market Gainers

    Benzinga | Aug. 5, 2013 | 08:12AM EST
  37. FDA Removes Clinical Hold on BioCryst's BCX 4161 -8K

    Benzinga | Aug. 1, 2013 | 13:14PM EST
  38. Benzinga's Top Pre-Market Gainers

    Benzinga | Aug. 1, 2013 | 08:17AM EST
  39. BioCryst Prices 4M Share Offering at $4.40/Share

    Benzinga | Jul. 31, 2013 | 21:12PM EST
  40. UPDATE: Bank of America Downgrades BioCryst Pharmaceuticals on Valuation

    Benzinga | Jul. 31, 2013 | 08:36AM EST
  41. Benzinga's Top Pre-Market Losers

    Benzinga | Jul. 31, 2013 | 08:18AM EST
  42. UPDATE: Bank of America Resumes Coverage on BioCryst Pharmaceuticals with Neutral Rating, $2 PT

    Benzinga | Feb. 4, 2013 | 02:05AM EST
  43. Benzinga's Small Cap Movers for Wednesday January 2, 2013

    Benzinga | Jan. 2, 2013 | 13:37PM EST
  44. Ballots Are In: Worst CEO in the Biotech Industry Is . . .

    YCharts | Dec. 7, 2012 | 03:49AM EST
  45. BioCryst Pharmaceuticals, Presidio Pharmaceuticals Terminate Merger Agreement

    Benzinga | Nov. 29, 2012 | 23:13PM EST
  46. BioCryst Broad-Spectrum Antiviral BCX4430 Shows Effective and Well Tolerated in Yellow Fever Preclinical Disease Model

    Benzinga | Nov. 11, 2012 | 23:36PM EST
  47. BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus | Nov. 8, 2012 | 11:36AM EST
  48. BioCryst Announces Withdrawal of BCX5191 Investigational New Drug Application Following Discussion With FDA

    Benzinga | Oct. 30, 2012 | 12:10PM EST
  49. Benzinga's M&A Chatter for Thursday October 18, 2012

    Benzinga | Oct. 18, 2012 | 15:10PM EST
  50. BioCryst Pharmaceuticals and Presidio Pharmaceuticals to Merge

    Benzinga | Oct. 18, 2012 | 01:37AM EST
Trading Center